138 related articles for article (PubMed ID: 38051880)
1. Hydroxytyrosol and Parkinson's disease: protective actions against alpha-synuclein toxicity.
Hornedo-Ortega R; Espinosa-Oliva AM
Neural Regen Res; 2024 Jul; 19(7):1427-1428. PubMed ID: 38051880
[No Abstract] [Full Text] [Related]
2. Corrigendum to "Protective effects of hydroxytyrosol against α-synuclein toxicity on PC12 cells and fibril formation" [Food Chem. Toxicol. 120 (2018) 41-49].
Hornedo-Ortega R; Cerezo AB; Troncoso AM; Garcia-Parrilla MC
Food Chem Toxicol; 2018 Nov; 121():719. PubMed ID: 30253891
[No Abstract] [Full Text] [Related]
3. Cytoprotective effect of chlorogenic acid against α-synuclein-related toxicity in catecholaminergic PC12 cells.
Teraoka M; Nakaso K; Kusumoto C; Katano S; Tajima N; Yamashita A; Zushi T; Ito S; Matsura T
J Clin Biochem Nutr; 2012 Sep; 51(2):122-7. PubMed ID: 22962530
[TBL] [Abstract][Full Text] [Related]
4. Reynosin protects against neuronal toxicity in dopamine-induced SH-SY5Y cells and 6-hydroxydopamine-lesioned rats as models of Parkinson's disease: Reciprocal up-regulation of E6-AP and down-regulation of α-synuclein.
Ham A; Kim DW; Kim KH; Lee SJ; Oh KB; Shin J; Mar W
Brain Res; 2013 Aug; 1524():54-61. PubMed ID: 23751361
[TBL] [Abstract][Full Text] [Related]
5. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
7. Protective effects of hydroxytyrosol against α-synuclein toxicity on PC12 cells and fibril formation.
Hornedo-Ortega R; Cerezo AB; Troncoso AM; Garcia-Parrilla MC
Food Chem Toxicol; 2018 Oct; 120():41-49. PubMed ID: 29964084
[TBL] [Abstract][Full Text] [Related]
8. Nurr1 and Retinoid X Receptor Ligands Stimulate Ret Signaling in Dopamine Neurons and Can Alleviate α-Synuclein Disrupted Gene Expression.
Volakakis N; Tiklova K; Decressac M; Papathanou M; Mattsson B; Gillberg L; Nobre A; Björklund A; Perlmann T
J Neurosci; 2015 Oct; 35(42):14370-85. PubMed ID: 26490873
[TBL] [Abstract][Full Text] [Related]
9. Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease.
Er S; Airavaara M
Biochem Soc Trans; 2023 Feb; 51(1):245-257. PubMed ID: 36794783
[TBL] [Abstract][Full Text] [Related]
10. Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone.
Lee JS; Kanai K; Suzuki M; Kim WS; Yoo HS; Fu Y; Kim DK; Jung BC; Choi M; Oh KW; Li Y; Nakatani M; Nakazato T; Sekimoto S; Funayama M; Yoshino H; Kubo SI; Nishioka K; Sakai R; Ueyama M; Mochizuki H; Lee HJ; Sardi SP; Halliday GM; Nagai Y; Lee PH; Hattori N; Lee SJ
Brain; 2019 Sep; 142(9):2845-2859. PubMed ID: 31312839
[TBL] [Abstract][Full Text] [Related]
11. Melatonin, protocatechuic acid and hydroxytyrosol effects on vitagenes system against alpha-synuclein toxicity.
Gallardo-Fernández M; Hornedo-Ortega R; Cerezo AB; Troncoso AM; García-Parrilla MC
Food Chem Toxicol; 2019 Dec; 134():110817. PubMed ID: 31521636
[TBL] [Abstract][Full Text] [Related]
12. Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity.
Moszczynska A; Saleh J; Zhang H; Vukusic B; Lee FJ; Liu F
J Mol Neurosci; 2007; 32(3):217-27. PubMed ID: 17873367
[TBL] [Abstract][Full Text] [Related]
13. Serological Analysis of Alpha-synuclein and NF-κB in Parkinson's Disease Patients.
Gupta V; Garg RK; Khattri S
J Clin Diagn Res; 2015 May; 9(5):BC01-4. PubMed ID: 26155470
[TBL] [Abstract][Full Text] [Related]
14. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease.
Nwabufo CK; Aigbogun OP
J Neurol; 2022 Nov; 269(11):5762-5786. PubMed ID: 35831620
[TBL] [Abstract][Full Text] [Related]
16. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
van Rooijen BD; Claessens MM; Subramaniam V
Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of alpha mangostin on rotenone induced toxicity in rat model of Parkinson's disease.
Parkhe A; Parekh P; Nalla LV; Sharma N; Sharma M; Gadepalli A; Kate A; Khairnar A
Neurosci Lett; 2020 Jan; 716():134652. PubMed ID: 31778768
[TBL] [Abstract][Full Text] [Related]
18. Advances in understanding the function of alpha-synuclein: implications for Parkinson's disease.
Calabresi P; Di Lazzaro G; Marino G; Campanelli F; Ghiglieri V
Brain; 2023 Sep; 146(9):3587-3597. PubMed ID: 37183455
[TBL] [Abstract][Full Text] [Related]
19. Calcium/calmodulin-dependent serine protein kinase exacerbates mitochondrial calcium uniporter-related mitochondrial calcium overload by phosphorylating α-synuclein in Parkinson's disease.
Zhang Q; Huang Y; Wu A; Duan Q; He P; Huang H; Gao Y; Nie K; Liu Q; Wang L
Int J Biochem Cell Biol; 2023 Apr; 157():106385. PubMed ID: 36754160
[TBL] [Abstract][Full Text] [Related]
20. CSF-derived extracellular vesicles from patients with Parkinson's disease induce symptoms and pathology.
Herman S; Djaldetti R; Mollenhauer B; Offen D
Brain; 2023 Jan; 146(1):209-224. PubMed ID: 35881523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
